30 results about "Secondary amenorrhea" patented technology

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.

The invention discloses a new medicine for dredging water and regulating menstruation. Chinese medicine, raw and cooked rehmannia root, safflower, Chinese yam, angelica, and leeches are used as raw materials. During preparation, the above-mentioned traditional Chinese medicine is soaked in water, decocted to obtain juice, after distillation, reflux, filtration, and clarification, the supernatant is autoclaved and bottled. into oral liquid. The medicine of the invention has the advantages of good curative effect and high cure rate when treating women with less menstrual flow and secondary amenorrhea.

The invention relates to a modulator of nonsteroidal progesterone receptor with a structure of the general formula I or an acceptable salt on pharmacy and a preparation method thereof. The invention also relates to drug combination including compounds of the general formula I or an acceptable salt on pharmacy thereof and the antagonist activity of progesterone receptor which is provided by the compounds of the general formula I or the acceptable salt on pharmacy thereof; therefore, the invention can be used for preparing nonsteroidal drugs to prevent and (or) or treat symptoms or diseases such as secondary amenorrhea, functional bleeding disorder, uterine fibroids, endometriosis, polycystic ovary syndrome, breast cancer, contraceptive, induced labor, and termination of pregnancy, etc.

The invention provides a progesterone ethosome. Progesterone is encapsulated in an ethosome. The progesterone ethosome comprises the following components in percentage by weight: 0.1 to 1 percent of progesterone, 1 to 8 percent of lipid materials, 0 to 0.6 percent of cholesterol, 20 to 50 percent of short-chain alcohols, 0 to 3 percent of nonionic surfactant and the balance of water. The preparation method comprises the following steps of: mixing and dissolving the progesterone, the lipid materials, the cholesterol and the short-chain alcohols to prepare an alcohol phase; with stirring, adding the alcohol phase into a nonionic surfactant-containing aqueous phase to prepare primary emulsion under the condition of stirring; homogenizing the primary emulsion under a high pressure to obtain asuspension; stirring the ethosome suspension for 15 to 30 minutes to perform emulsification for the second time; and curing the suspension by cooling the suspension at 0 to 4 DEG C to obtain the progesterone ethosome. Because the high-pressure homogenization method is adopted to prepare the progesterone ethosome, the progesterone ethosome is low in stimulation to skin and high in transdermal delivery ability, and metal ion pollution which is easy to cause by the probe ultrasound method of the traditional homogenization method is avoided. Therefore, the progesterone ethosome is suitable for industrial production. The progesterone ethosome can be prepared into a transdermal drug delivery system, a mucosal drug delivery system, and topical dosage forms, such as a paster, a gel and the like. The progesterone ethosome is mainly applied to hormone replacement therapy, secondary amenorrhea, functional aplastic bleeding, premenstrual syndrome and the like clinically.